All In Biotech

Drug Trial Radar · NCT03390504

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 629 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

629

Actual

Start

Mar 23, 2018

Primary completion

Apr 15, 2024

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

Conditions

  • Urothelial Cancer

Interventions

  • ErdafitinibDrug

    Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

  • VinflunineDrug

    Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.

  • DocetaxelDrug

    Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.

  • PembrolizumabDrug

    Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.

  • Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Device

    FGFRi CTA will be used to determine molecular eligibility.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)

Locations

345 sites in 27 countries. Site status is shown where the registry gives one.

  • Alaska Urological Institute dba Alaska Clinical Research Center

    Anchorage, Alaska

  • University of Calif Davis Medical Center

    Sacramento, California

  • St. Helena Hospital - Martin-O'Neil Cancer Center

    St. Helena, California

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • Mid Florida Hematology Oncology

    Orange, Florida

  • Piedmont Cancer Institute

    Atlanta, Georgia

  • Rush University

    Chicago, Illinois

  • Edward Hines Jr V A Hospital

    Hines, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Maryland Oncology Hematology, PA

    Lanham, Maryland

  • University of Michigan Health System

    Ann Arbor, Michigan

  • VA Sierra Nevada Health Care System

    Reno, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Weill Cornell Medical College

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina

  • W G Bill Hefner VA Medical Center

    Salisbury, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas

  • Texas Oncology-Memorial City

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology Tyler

    Tyler, Texas

  • INOVA Dwiight &Martha Schar Cancer Institute

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • VA Puget Sound Healthcare System

    Seattle, Washington

  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes

    Buenos Aires, Argentina

  • Centro Oncológico Korben

    Buenos Aires, Argentina

  • CEMIC Saavedra

    Buenos Aires, Argentina

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina

  • Centro Urologico Profesor Bengio

    Córdoba, Argentina

  • Hospital Privado de Comunidad

    Mar del Plata, Argentina

  • Centro de Investigacion Pergamino SA

    Pergamino, Argentina

  • Clínica Viedma

    Viedma, Argentina

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Australia

  • St George Hospital

    Kogarah, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Frankston Hospital

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

Showing 40 of 345 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.